What is LucasBio's pipeline?

LucasBio's pipeline consists of cell therapy programs being developed to treat viral infections and refractory diseases. The pipeline page provides an overview of the programs and their clinical development status.

What diseases are targeted by LucasBio's cell therapy pipeline?

LucasBio's cell therapy pipeline includes programs targeting viral infections and refractory diseases. Specific disease indications are listed for each pipeline program in the pipeline table.

What clinical development stages are shown on the LucasBio pipeline page?

The LucasBio pipeline page presents development stages including Pending Approval, Phase 1, Phase 1/2, and Phase 2 under the Advanced Regenerative Medicine (ARM) Clinical Study.

DTK08 is a LucasBio pipeline program associated with EBV-Associated Diseases. The pipeline table provides its current clinical development status and reference information.

Where can I find information about LucasBio's pipeline programs?

LucasBio provides pipeline information on its Pipeline page, including individual pipeline codes, associated diseases, clinical development stages, and reference information.

Pipeline | LUCASBIO

DTK

Direct Targeting Killer Cell

Orange: MFDS-Clinical Trial

Navy: Advanced Regenerative Medicine Clinical Study

LucasBio Cell Therapy Pipeline and Clinical Development Status
Pipeline	Disease	Pending Approval	Phase 1	Reference
Pipeline	Disease	Pending Approval	Advanced Regenerative Medicine (ARM) Clinical Study	Reference
DTK01	Prolonged COVID-19 (Autologous)	Clinical development progress: 96%		Publication Clinical trial
DTK02	Severe/Prolonged COVID-19 (Allogeneic)	Clinical development progress: 47%		Publication Clinical trial
DTK03	CMV, BKV, EBV Infection after Adult HSCT + Anti-Cancer Therapy (Allogeneic)	Clinical development progress: 75%		Clinical trial
DTK04	CMV, BKV, EBV Infection after Pediatric HSCT (Allogeneic)	Clinical development progress: 60%		Clinical trial
DTK05	CMV Retinitis (Autologous)	Clinical development progress: 60%		Clinical trial
DTK06	BKV Hemorrhagic Cystitis (Allgoeneic)	Clinical development progress: 75%		Clinical trial
DTK07	BKV Nephropathy	Clinical development progress: 25%
DTK08	EBV-Associated Diseases	Clinical development progress: 25%

View mechanism of action

CIK

Cytokine Induced Killer Cell

Orange: MFDS-Clinical Trial

Navy: Advanced Regenerative Medicine Clinical Study

LucasBio Cell Therapy Pipeline and Clinical Development Status
Pipeline	Disease	Pending Approval	Phase 1	Reference
Pipeline	Disease	Pending Approval	Advanced Regenerative Medicine (ARM) Clinical Study	Reference
CIK01	Lymphoma post-HSCT	Clinical development progress: 95%		Publication Clinical trial
CIK02	Maintenance in High Risk Lymphoma	Clinical development progress: 50%

View mechanism of action

DSC

Decidual Stromal Cell

Orange: MFDS-Clinical Trial

Navy: Advanced Regenerative Medicine Clinical Study

LucasBio Cell Therapy Pipeline and Clinical Development Status
Pipeline	Disease	Pending Approval	Phase 1	Reference
Pipeline	Disease	Pending Approval	Advanced Regenerative Medicine (ARM) Clinical Study	Reference
DSC01	Inflammatory Bowel Disease	Clinical development progress: 15%
DSC02	Graft-versus-host disease	Clinical development progress: 15%

View mechanism of action

Pipeline | LUCASBIO

SITE MAP

Pipeline & Science

DTK

CIK

DSC

FAQ

자주 묻는 질문